Brief: Santhera Pharmaceuticals: Completes Divestment Of Raxone/Idebenone Business To Chiesi Farmaceutici S.P.A.

Santhera Pharmaceuticals Holding AG

31/07/2023 06:02

July 31 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA PHARMACEUTICALS (SIX: SANN) ANNOUNCES FULL
DIVESTMENT
OF ITS RAXONE®/IDEBENONE BUSINESS WORLDWIDE AND FOR ALL
INDICATIONS TO CHIESI FARMACEUTICI S.P.A.
    * TRANSACTION REPLACES EXISTING LICENSE AGREEMENT BETWEEN
TWO
COMPANIES ENTERED INTO IN 2019
    * CHIESI GROUP ASSUMES FRENCH REIMBURSEMENT LIABILITY OF EUR
25.3
MILLION FROM SANTHERA
    * SANTHERA RETAINS CONTINGENT VALUE FORLHON IN U.S. AND/OR
OTHER
INDICATIONS WORLDWIDE
    * SANTHERA CEASES ALL RAXONE-RELATED ACTIVITIES
ANDINTENSIFIES
COMMERCIAL PREPARATION FOR DUCHENNE MUSCULAR DYSTROPHY CANDIDATE
VAMOROLONEIN EUROPE

Source text for Eikon:  ID:nGNE8lmc2G 
Further company coverage:  SANN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))